PharVision Advisers’s Medpace MEDP Stock Holding History

PharVision Advisers’s Portfolio MEDP Stock Details MEDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-447	Closed	-$230K	–	886
2025 Q3	$230K	Buy	+447	New	+$195K	0.13%	394

Other funds holding MEDP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PharVision Advisers's MEDP Position: Q4 2025 in Review

PharVision Advisers sold out of Medpace (MEDP) in Q4 2025, closing a stake of 447 shares — an estimated $230K sold.

PharVision Advisers first reported a position in MEDP in Q3 2025 and held it in 1 quarter. The position peaked at $230K in Q3 2025. 785 funds tracked by Wall St. Rank hold MEDP as of Q4 2025.

PharVision Advisers reported no remaining Medpace position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 447 Medpace shares in Q4 2025, an estimated $230K.
PharVision Advisers first reported a position in Medpace in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Medpace position peaked at $230K in Q3 2025.
785 funds tracked by Wall St. Rank held Medpace as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.